The protease ADAM17 at the crossroads of disease: revisiting its significance in inflammation, cancer, and beyond
The FEBS Journal · 2024-01 · 291 (1) · 10-24
DOI: 10.1111/febs.16923 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FEBS Journal, online erschienen am 11.08.2023. Verfasst von Mohamed I Saad und 1 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia. Hauptthemen laut MEDLINE: ADAM Proteins, Neoplasms. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council of Australia, U.S. Department of Defense.
Abstract (Originalsprache)
The protease A Disintegrin And Metalloproteinase 17 (ADAM17) plays a central role in the pathophysiology of several diseases. ADAM17 is involved in the cleavage and shedding of at least 80 known membrane‐tethered proteins, which subsequently modulate several intracellular signaling pathways, and therefore alter cell behavior. Dysregulated expression and/or activation of ADAM17 has been linked to a wide range of autoimmune and inflammatory diseases, cancer, and cardiovascular disease. In this review, we provide an overview of the current state of knowledge from preclinical models and clinical data on the diverse pathophysiological roles of ADAM17, and discuss the mechanisms underlying ADAM17‐mediated protein shedding and the potential therapeutic implications of targeting ADAM17 in these diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
- Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.
- South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide, SA, Australia.
ORCID-Profile: Mohamed I Saad, Brendan J Jenkins
Förderung
- National Health and Medical Research Council of Australia
- U.S. Department of Defense
Zitieren
APA
Saad, M. I., & Jenkins, B. J. (2024). The protease ADAM17 at the crossroads of disease: revisiting its significance in inflammation, cancer, and beyond. The FEBS Journal, 291(1), 10-24. https://doi.org/10.1111/febs.16923
Vancouver
Saad MI, Jenkins BJ. The protease ADAM17 at the crossroads of disease: revisiting its significance in inflammation, cancer, and beyond. The FEBS Journal. 2024;291(1):10-24. doi:10.1111/febs.16923
BibTeX
@article{Saad2024,
author = {Saad, Mohamed I and Jenkins, Brendan J},
title = {The protease ADAM17 at the crossroads of disease: revisiting its significance in inflammation, cancer, and beyond},
journal = {The FEBS Journal},
year = {2024},
volume = {291},
number = {1},
pages = {10--24},
doi = {10.1111/febs.16923}
}
EUVIMED